John Renger - 04 Oct 2022 Form 4 Insider Report for Cerevel Therapeutics Holdings, Inc.

Role: Chief Scientific Officer
Signature: /s/ Mark Bodenrader, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 04 Oct 2022
Net transactions value: -$560,922
Form type: 4
Filing time: 06 Oct 2022, 16:59:27 UTC
Previous filing: 12 Aug 2022
Next filing: 03 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CERE	Common Stock	Options Exercise	$35,063	+10,018	+370%	$3.50^*	12,722	04 Oct 2022	Direct	F1
transaction	CERE	Common Stock	Options Exercise	$154,015	+14,982	+118%	$10.28	27,704	04 Oct 2022	Direct	F1
transaction	CERE	Common Stock	Sale	$750,000	-25,000	-90%	$30.00	2,704	04 Oct 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-10,018	-12%	$0.000000	70,128	04 Oct 2022	Common Stock	10,018	$3.50	Direct	F1, F2
transaction	CERE	Stock Option (Right to Buy)	Options Exercise	$0	-14,982	-11%	$0.000000	119,933	04 Oct 2022	Common Stock	14,982	$10.28	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These transactions were effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2021 adopted by the Reporting Person.
F2	25% of the shares subject to this option vested and became exercisable on April 8, 2020, with the remainder vesting in thirty-six (36) equal monthly installments thereafter.